Re: Farmas USA
el que tenga CMRX desde antes de diciembre... necesitará un resucitador de muertos, por lo menos jeje
para quien no la siga:
las CMRX "lost over 80% of their value this morning on exceptionally high volume due to the failure of its lead product candidate, brincidofovir (CMX001), in a late-stage study." dic'15
pero: "Piper Jaffray analyst Joshua Schimmer boosted his price target for Chimerix to $18, up from his prior target of $11, as he believes that odds are favorable that brincidofovir will gain approval for treating adenovirus and smallpox. He also noted that the potential still exists for brincidofovir to be used as a treatment for organ transplant, even after the early results from the drugs SUPPRESS trial indicated otherwise. " ene'16
y: "The company reported $343 million in capital available to fund operations, which “provides the financial strength to advance brincidofovir and our earlier drug candidates and to continue to build value,” Berrey (CEO) said." a parte de recortar 20% trabajadores. mar'16
resumen: fail, desplome, continue
webcasts de varias presentaciones en http://ir.chimerix.com/events.cfm
A mí me llama la atención. Será por esa compasión humana de creer que es posible levantarse despues de caerse?
Le echaremos un ojo a la call mas reciente de la CEO, a ver si nos vende la moto. Meter un % minúsculo, tipo "fondo perdido", es una posibilidad interesante.
CMRX